Now showing items 1-17 of 17

    • The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. 

      Schneider, N; Strauss, DC; Smith, MJ; Miah, AB; Zaidi, S; Benson, C; van Houdt, WJ; Jones, RL; Hayes, AJ; Fisher, C; Thway, K (2017-07)
      The grading of soft tissue sarcomas is one of the most important prognostic factors and determines patient management. Although grading of most adult-type soft tissue sarcomas on biopsies correlates highly with the final ...
    • Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. 

      Brunner, C; Davies, NM; Martin, RM; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, G; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Donovan, J; Hamdy, FC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL Consortium,; Zuccolo, L (2017-01)
      Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies. The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially ...
    • Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. 

      Bonilla, C; Lewis, SJ; Rowlands, M-A; Gaunt, TR; Davey Smith, G; Gunnell, D; Palmer, T; Donovan, JL; Hamdy, FC; Neal, DE; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, GG; Wiklund, F; Grönberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL consortium; Lathrop, M; Martin, RM; Holly, JMP (2016-10)
      Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using genetic variants as instruments for IGF peptides, we investigated whether these associations are ...
    • Blood lipids and prostate cancer: a Mendelian randomization analysis. 

      Bull, CJ; Bonilla, C; Holly, JMP; Perks, CM; Davies, N; Haycock, P; Yu, OHY; Richards, JB; Eeles, R; Easton, D; Kote-Jarai, Z; Amin Al Olama, A; Benlloch, S; Muir, K; Giles, GG; MacInnis, RJ; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Micheal, A; Pandha, H; Smith, GD; Lewis, SJ; Martin, RM; PRACTICAL consortium (2016-06)
      Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ...
    • Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. 

      Carceller, F; Jerome, NP; Miyazaki, K; Collins, DJ; Orton, MR; d'Arcy, JA; Wallace, T; Moreno, L; Pearson, ADJ; Zacharoulis, S; Leach, MO; Marshall, LV; Koh, D-M (2017-02)
      Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) have been used as imaging biomarkers in adults with high-grade gliomas (HGGs). We incorporated free-breathing DW-MRI and DCE-MRI, ...
    • Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. 

      Leongamornlert, DA; Saunders, EJ; Wakerell, S; Whitmore, I; Dadaev, T; Cieza-Borrella, C; Benafif, S; Brook, MN; Donovan, JL; Hamdy, FC; Neal, DE; Muir, K; Govindasami, K; Conti, DV; Kote-Jarai, Z; Eeles, RA (2019-09)
      <h4>Background</h4>Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis.<h4>Objective</h4>To quantify the frequency of germline DNA repair gene mutations in UK ...
    • Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 

      Lophatananon, A; Stewart-Brown, S; Kote-Jarai, Z; Olama, AAA; Garcia, SB; Neal, DE; Hamdy, FC; Donovan, JL; Giles, GG; Fitzgerald, LM; Southey, MC; Pharoah, P; Pashayan, N; Gronberg, H; Wiklund, F; Aly, M; Stanford, JL; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Lin, H-Y; Sellers, T; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; APCB BioResource; PRACTICAL consortium; Easton, D; Eeles, RA; Muir, K (2017-08)
      <h4>Background</h4>Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.<h4>Methods</h4>We ...
    • Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. 

      Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; Bloomfield, DJ; Chan, C; Churn, M; Cleator, S; Coles, CE; Goodman, A; Harnett, A; Hopwood, P; Kirby, AM; Kirwan, CC; Morris, C; Nabi, Z; Sawyer, E; Somaiah, N; Stones, L; Syndikus, I; Bliss, JM; Yarnold, JR; FAST-Forward Trial Management Group (2020-05)
      <h4>Background</h4>We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international ...
    • Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. 

      Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; Chu, W; Ford, D; Tolan, S; Jain, S; Martin, A; Staffurth, J; Camilleri, P; Kancherla, K; Frew, J; Chan, A; Dayes, IS; Henderson, D; Brown, S; Cruickshank, C; Burnett, S; Duffton, A; Griffin, C; Hinder, V; Morrison, K; Naismith, O; Hall, E; van As, N; PACE Trial Investigators (2019-11)
      <h4>Background</h4>Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ...
    • Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

      Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-06)
      PURPOSE:To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
    • Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. 

      Henderson, DR; de Souza, NM; Thomas, K; Riches, SF; Morgan, VA; Sohaib, SA; Dearnaley, DP; Parker, CC; van As, NJ (2016-06)
      In active surveillance (AS) for prostate cancer there are few data on long-term outcomes associated with novel imaging markers.To determine long-term outcomes with respect to the apparent diffusion coefficient (ADC) derived ...
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

      Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-01-04)
      BACKGROUND:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition ...
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. 

      Spurdle, AB; Couch, FJ; Parsons, MT; McGuffog, L; Barrowdale, D; Bolla, MK; Wang, Q; Healey, S; Schmutzler, R; Wappenschmidt, B; Rhiem, K; Hahnen, E; Engel, C; Meindl, A; Ditsch, N; Arnold, N; Plendl, H; Niederacher, D; Sutter, C; Wang-Gohrke, S; Steinemann, D; Preisler-Adams, S; Kast, K; Varon-Mateeva, R; Ellis, S; Frost, D; Platte, R; Perkins, J; Evans, DG; Izatt, L; Eeles, R; Adlard, J; Davidson, R; Cole, T; Scuvera, G; Manoukian, S; Bonanni, B; Mariette, F; Fortuzzi, S; Viel, A; Pasini, B; Papi, L; Varesco, L; Balleine, R; Nathanson, KL; Domchek, SM; Offitt, K; Jakubowska, A; Lindor, N; Thomassen, M; Jensen, UB; Rantala, J; Borg, Å; Andrulis, IL; Miron, A; Hansen, TVO; Caldes, T; Neuhausen, SL; Toland, AE; Nevanlinna, H; Montagna, M; Garber, J; Godwin, AK; Osorio, A; Factor, RE; Terry, MB; Rebbeck, TR; Karlan, BY; Southey, M; Rashid, MU; Tung, N; Pharoah, PDP; Blows, FM; Dunning, AM; Provenzano, E; Hall, P; Czene, K; Schmidt, MK; Broeks, A; Cornelissen, S; Verhoef, S; Fasching, PA; Beckmann, MW; Ekici, AB; Slamon, DJ; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Chang-Claude, J; Flesch-Janys, D; Rudolph, A; Seibold, P; Aittomäki, K; Muranen, TA; Heikkilä, P; Blomqvist, C; Figueroa, J; Chanock, SJ; Brinton, L; Lissowska, J; Olson, JE; Pankratz, VS; John, EM; Whittemore, AS; West, DW; Hamann, U; Torres, D; Ulmer, HU; Rüdiger, T; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Van Asperen, CJ; Eccles, DM; Tapper, WJ; Durcan, L; Jones, L; Peto, J; dos-Santos-Silva, I; Fletcher, O; Johnson, N; Dwek, M; Swann, R; Bane, AL; Glendon, G; Mulligan, AM; Giles, GG; Milne, RL; Baglietto, L; McLean, C; Carpenter, J; Clarke, C; Scott, R; Brauch, H; Brüning, T; Ko, Y-D; Cox, A; Cross, SS; Reed, MWR; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Gronwald, J; Dörk, T; Bogdanova, N; Park-Simon, T-W; Hillemanns, P; Haiman, CA; Henderson, BE; Schumacher, F; Le Marchand, L; Burwinkel, B; Marme, F; Surovy, H; Yang, R; Anton-Culver, H; Ziogas, A; Hooning, MJ; Collée, JM; Martens, JWM; Tilanus-Linthorst, MMA; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Lindblom, A; Margolin, S; Joseph, V; Robson, M; Rau-Murthy, R; González-Neira, A; Arias, JI; Zamora, P; Benítez, J; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Peterlongo, P; Zaffaroni, D; Barile, M; Capra, F; Radice, P; Teo, SH; Easton, DF; Antoniou, AC; Chenevix-Trench, G; Goldgar, DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators (2014-12-23)
      <h4>Introduction</h4>The distribution of histopathological features of invasive breast tumors in BRCA1 or BRCA2 germline mutation carriers differs from that of individuals with no known mutation. Histopathological features ...
    • Separation of type and grade in cervical tumours using non-mono-exponential models of diffusion-weighted MRI. 

      Winfield, JM; Orton, MR; Collins, DJ; Ind, TEJ; Attygalle, A; Hazell, S; Morgan, VA; deSouza, NM (2017-02)
      <h4>Objectives</h4>Assessment of empirical diffusion-weighted MRI (DW-MRI) models in cervical tumours to investigate whether fitted parameters distinguish between types and grades of tumours.<h4>Methods</h4>Forty-two ...
    • Validating a robust double-quantum-filtered (1) H MRS lactate measurement method in high-grade brain tumours. 

      Payne, GS; Harris, LM; Cairns, GS; Messiou, C; deSouza, NM; Macdonald, A; Saran, F; Leach, MO (2016-10)
      (1) H MRS measurements of lactate are often confounded by overlapping lipid signals. Double-quantum (DQ) filtering eliminates lipid signals and permits single-shot measurements, which avoid subtraction artefacts in moving ...
    • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. 

      Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; Kostaras, E; Nathan, M; Wotherspoon, A; Gao, Z-H; Shi, Y; Van den Eynden, G; Daley, F; Peckitt, C; Tan, X; Salman, A; Lazaris, A; Gazinska, P; Berg, TJ; Eltahir, Z; Ritsma, L; Van Rheenen, J; Khashper, A; Brown, G; Nystrom, H; Sund, M; Van Laere, S; Loyer, E; Dirix, L; Cunningham, D; Metrakos, P; Reynolds, AR (2016-11)
      The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...
    • Volumetry of the dominant intraprostatic tumour lesion: intersequence and interobserver differences on multiparametric MRI. 

      Harvey, H; Orton, MR; Morgan, VA; Parker, C; Dearnaley, D; Fisher, C; deSouza, NM (2017-03)
      <h4>Objective</h4>To establish the interobserver reproducibility of tumour volumetry on individual multiparametric (mp) prostate MRI sequences, validate measurements with histology and determine whether functional to ...